{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344580","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2026-08-11T20:05:15+00:00","discovered_at":"2026-08-11T20:06:00.542478+00:00","generated_at":"2026-08-11T20:06:17.889004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bolt Biotherapeutics reports Q2 2026 operating loss of $8.4M; cash $18.1M funds into Q1 2027","bullets":["Cash, equivalents and marketable securities $18.1M as of Jun 30, 2026; expected to fund operations into 1Q 2027.","Collaboration revenue $5K vs $1.8M in Q2 2025; R&D expenses $5.1M vs $7.5M; G&A $2.4M vs $3.5M.","Loss from operations $8.4M in Q2 2026 vs $9.2M in Q2 2025, driven by restructuring-related cost reductions.","BDC-4182 Phase 1/2 in gastric/GEJ cancer ongoing; Cohort 4 dosing at 4.0 mg/kg; initial data expected with 3Q 2026 results.","CEO Willie Quinn cites well-tolerated profile and activity consistent with immune-stimulating mechanism for BDC-4182."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344580","json":"https://secwatch.observer/filing/0001193125-26-344580.json","markdown":"https://secwatch.observer/filing/0001193125-26-344580.md","text":"https://secwatch.observer/filing/0001193125-26-344580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/0001193125-26-344580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/bolt-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:06:17.889004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}